Ms. Allison Hults, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2829 Church St, Stissing Mountain School, Pine Plains, NY 12567 Phone: 518-398-7181 Fax: 518-398-9049 |
Ms. Lisa M Michetti, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 44 Stissing Mountain Dr, Pine Plains, NY 12567 Phone: 518-391-9511 |
Mrs. Lynn Ann Gillard, LCSWR Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 2829 Church St, Pine Plains, NY 12567 Phone: 518-398-7181 |
Mrs. Amy M. Duncan, LMSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 41 Academy St, Pine Plains, NY 12567 Phone: 518-398-3000 Fax: 518-398-1141 |
News Archive
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
A team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Scientific Director of the institute and Director of the Hematopoiesis and Cancer research unit, will be publishing an important breakthrough in tomorrow's issue of Immunity, a scientific journal from the Cell Press group. The researchers identified a new regulator playing a critical role in the development B cells, which produce antibodies.
The implant, manufactured by Santa Barbara-based Sientra, can be used for breast tissue reconstruction for women of any age and for breast augmentation in women 22 or older. The approval resulted from three years of clinical studies on almost 1,800 patients. Tightening of the area around the implant, re-operation, implant removal, uneven appearance and infection were some of the complications experienced during the study. Sientra is required to continue studies on the implant's long-term safety, effectiveness and risks of rare diseases under the approval.
Children with invasive bloodstream infections treated with a single antibiotic are just as likely to overcome their infections as those who get two-drug therapy, but at half the risk of drug-induced kidney damage, according to results of a Johns Hopkins Children's Center study.
President-elect Joe Biden is still being blocked from launching his official transition while President Donald Trump contests the outcome of the election. That could be particularly dangerous for public health as COVID-19 spreads around the country at an alarming rate.
› Verified 1 days ago